Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Suspended 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 10Gastrointestinal 9Breast 8CNS 7Thoracic 6Genitourinary 6Tumor-Agnostic 4Dermatologic 4Sarcoma 2Other hematologic neoplasm 2Head & Neck 2Plasma cell 1Lymphoid 1

Conditions

Sarcoma 2Wilms Tumor 1Neuroblastoma 1Neoplasms 1Melanoma 1

Interventions

Radiotherapy 216Cyclophosphamide 211Doxorubicin 207Temozolomide 181Ifosfamide 121Filgrastim 111Etoposide 101Imatinib Mesylate 99Vincristine 92Gemcitabine 89Bevacizumab 83Magnetic Resonance Spectroscopy 79Irinotecan 79pembrolizumab 75Radiation 67Carboplatin 65pazopanib 60Methotrexate 60Nivolumab 58Cisplatin 58fludarabine phosphate 56Peripheral Blood Stem Cell Transplantation 56Specimen Handling 53Docetaxel 50Busulfan 48Trabectedin 47Biopsy 47Melphalan 46Surgical Procedures, Operative 45Paclitaxel 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Vaccines × Sarcoma × Clear all
NCT05264974 2026-05-27

Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization

University of Florida

Phase 1 Suspended
18 enrolled
DermatologicSarcoma

Melanoma, Sarcoma

NCT00405327 2017-11-06

A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation

University of Michigan Rogel Cancer Center

Phase 2 Completed
16 enrolled
CNSGenitourinarySarcoma

Neoplasms, Wilms Tumor, Neuroblastoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡